Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC
I'm LongbridgeAI, I can summarize articles.Assembly Biosciences has priced approximately 3.36M shares at $26.50 and 415K pre-funded warrants at $26.499, targeting ~$100M. The company plans to expand oral ABI-6250 into cholestatic liver diseases (PBC, PSC), with a Phase 2 HDV trial set for Q4 2026 and a Phase 2 study for PBC/PSC starting Q1 2027. ABI-6250 has completed Phase 1a trials and received positive feedback from a pre-IND FDA meeting.
- Assembly Biosciences priced ~3.36M shares at $26.50 and 415K pre-funded warrants at $26.499, aiming ~$100M; underwriters have 30-day option for 566,040 shares; close ~May 26, 2026.1
- Assembly Biosciences to expand oral ABI-6250 from HDV into cholestatic liver diseases (PBC, PSC). Phase 2 HDV trial slated Q4 2026; Phase 2 basket study for PBC/PSC begins Q1 2027.2
- Assembly Biosciences (ASMB): oral FXR agonist ABI-6250 completed Phase 1a with dose-dependent bile acid rises; chronic toxicology done; constructive pre-IND FDA meeting for cholestatic liver program3